1. Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation.
- Author
-
Saleh K, Arbab A, Ghez D, Bigenwald C, Cotteret S, Marzac C, Pasquier F, Pilorge S, Saada V, Vergé V, Ribrag V, and Castilla-Llorente C
- Subjects
- Humans, Immunotherapy, Adoptive adverse effects, Antigens, CD19 therapeutic use, Receptors, Antigen, T-Cell, Receptors, Chimeric Antigen, Lymphoma, Large B-Cell, Diffuse, Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndromes
- Abstract
Chimeric antigen receptor (CAR) T-cell therapy is currently approved for the treatment of B-cell non-Hodgkin lymphomas and B-cell acute lymphoblastic leukemia. Prolonged hematological toxicity is an emergent concern following CAR T cells and occurred in 30% of patients with unknown mechanism. Few cases of myelodysplastic syndrome (MDS) following CAR T-cell therapy were reported and attributed to previous chemotherapies in heavily pretreated patients. The authors report the case of a patient with diffuse large B-cell lymphoma treated with axicabtagene ciloleucel who developed prolonged hematological toxicity by day 28. During the follow-up, the diagnosis of MDS was made. The patient underwent allogenic hematological stem cell transplantation. The patient remains in complete remission of his lymphoma and MDS 19 months after hematological stem cell transplantation.
- Published
- 2023
- Full Text
- View/download PDF